Sean E. Harper
Chief Executive Officer at Amgen Rockville, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Bradway | M | 61 |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 18 years |
| David J. Scott | M | 71 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 years |
| Kevin Sharer | M | 76 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 32 years |
| Beth Seidenberg | M | 67 |
Jamanda Ltd.
 Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments.
Westlake Biopartners LLC
 Westlake Biopartners LLC Investment ManagersFinance Westlake Biopartners LLC (Westlake Biopartners) is a venture capital firm founded in 2018. The firm is headquartered in Westlake Village, California. | 10 years |
| Richard A. Markus | M | - |
Dantari, Inc.
 Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | - |
| Wanda Austin | M | 69 | 7 years | |
| Desmond Padhi | M | - |
Westlake Biopartners LLC
Westlake Biopartners LLC Investment ManagersFinance Westlake Biopartners LLC (Westlake Biopartners) is a venture capital firm founded in 2018. The firm is headquartered in Westlake Village, California. | 6 years |
| Marvin Gee | M | - |
3T Biosciences, Inc.
 3T Biosciences, Inc. BiotechnologyHealth Technology 3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA. | - |
| Leah Sibener | M | - |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology 3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA. | - |
| Esteban Santos | M | 56 | 17 years | |
| Catherine Bovenizer | F | 52 |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | - |
| David Reese | M | 61 | 19 years | |
| Stefan J. Scherer | M | - |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology 3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA. | 2 years |
| Matthew McAviney | M | - |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | - |
| Brian Druker | M | 68 | 6 years | |
| Tyler Jacks | M | 63 | 12 years | |
| Greg Garland | M | 66 | 11 years | |
| Matthew Busch | M | 50 | 20 years | |
| Ronald Sugar | M | 75 | 14 years | |
| Charles Holley | M | 67 | 7 years | |
| Ellen Kullman | F | 68 | 8 years | |
| Jonathan Graham | M | 63 | 9 years | |
| Lori Johnston | F | 59 | 8 years | |
| Robert Eckert | M | 69 | 21 years | |
| Robert Williams | M | 75 | 10 years | |
| L. Stephen Coles | M | 72 |
University of California, Berkeley
| 36 years |
| Brian M. McNamee | M | 67 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 years |
| Perrelli Brogan | F | - |
Westlake Biopartners LLC
Westlake Biopartners LLC Investment ManagersFinance Westlake Biopartners LLC (Westlake Biopartners) is a venture capital firm founded in 2018. The firm is headquartered in Westlake Village, California. | 3 years |
| Calveley Peter | M | - |
Westlake Biopartners LLC
Westlake Biopartners LLC Investment ManagersFinance Westlake Biopartners LLC (Westlake Biopartners) is a venture capital firm founded in 2018. The firm is headquartered in Westlake Village, California. | 3 years |
| Gina Knox | F | - |
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | - |
| Jennifer Neiman | F | - |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | - |
| Miranda Emma Thompson-Schwab | F | 59 |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | - |
| James Alexander Thompson-Schwab | M | 62 |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | - |
| Rachna Khosla | F | - | 11 years | |
| Mark J. Taisey | M | - | 10 years | |
| Pascal Touchon | M | 61 |
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | 2 years |
| Shelley Chu | M | 54 |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology 3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA. | - |
| Derek Miller | M | - | 21 years | |
| David Allison | M | 42 |
Westlake Biopartners LLC
Westlake Biopartners LLC Investment ManagersFinance Westlake Biopartners LLC (Westlake Biopartners) is a venture capital firm founded in 2018. The firm is headquartered in Westlake Village, California. | 1 years |
| Mira Chaurushiya | M | - |
Westlake Biopartners LLC
Westlake Biopartners LLC Investment ManagersFinance Westlake Biopartners LLC (Westlake Biopartners) is a venture capital firm founded in 2018. The firm is headquartered in Westlake Village, California. | 2 years |
| Mark E. Davis | M | - |
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | 2 years |
| Bryan Irving | M | 60 |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology 3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA. | 1 years |
| Liam Ratcliffe | M | 60 |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | - |
| John Leonard | M | 66 |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology 3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA. | 2 years |
| Donald A. McQuade | M | 82 |
University of California, Berkeley
| 38 years |
| Marc K. Hellerstein | M | 72 |
University of California, Berkeley
| 37 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Pamela Wapnick | F | 58 | 9 years | |
| Dennis Fenton | M | 72 | 27 years | |
| Christian Martin Itin | M | 59 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 6 years |
| Paul Eisenberg | M | - | 14 years | |
| Costas Christos Hamakiotes | M | - |
University of California, Berkeley
| 9 years |
| David W. Beier | M | 75 | 10 years | |
| Paul Jacobs | M | 61 |
University of California, Berkeley
| 9 years |
| Michael Kelly | M | 67 | 14 years | |
| Madhavan Balachandran | M | 73 | 20 years | |
| Qing Huang | M | 62 |
University of California, Berkeley
| 6 years |
| Carl Perez | M | - |
University of California, Berkeley
| 8 years |
| Jonathan Peacock | M | 66 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 4 years |
| Marc M. P. de Garidel | M | 66 | 15 years | |
| Matthias Alder | M | 59 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 6 years |
| Kamal H. Khayat | M | - |
University of California, Berkeley
| 7 years |
| Gregory L. Tewalt | M | - | - | |
| Diana McKenzie | F | 59 | 12 years | |
| Steven Galson | M | 67 | - | |
| Richard G. Wallace | M | - |
University of California, Berkeley
| 7 years |
| Raymond C. Jordan | M | 70 | 7 years | |
| Elliott Levy | M | 64 | 7 years | |
| Kent K. Sasaki | M | - |
University of California, Berkeley
| 6 years |
| Cynthia Patton | F | 62 | 15 years | |
| William Ashton | M | 73 | 16 years | |
| Yi Ning Zhao | M | 53 | 9 years | |
| Dave Butler | M | - |
University of California, Berkeley
| 7 years |
| Andreas Grauer | M | 63 | - | |
| Adam Rossman | M | 57 |
University of California, Berkeley
| 6 years |
| Richard Williams | M | 55 | 5 years | |
| Nathan Hardy | M | 48 | 10 years | |
| Kapil Dhingra | M | 64 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 3 years |
| George Morrow | M | 72 | 10 years | |
| David Meline | M | 66 | 6 years | |
| William Hsu | M | 57 |
University of California, Berkeley
| 6 years |
| Timothy Martin | M | 55 | 3 years | |
| Fred Hassan | M | 78 | 6 years | |
| Vance D. Coffman | M | 79 | 9 years | |
| Frederick Gluck | M | 88 | 13 years | |
| David Baltimore | M | 86 | 21 years | |
| Gil Omenn | M | 83 | 27 years | |
| Judith C. Pelham | F | 78 | 22 years | |
| Anna Richo | F | 63 | - | |
| Weijian Shan | M | 70 |
University of California, Berkeley
| 4 years |
| William P. Sheridan | M | 69 | 5 years | |
| Lisa Suennen | F | 58 |
University of California, Berkeley
| 5 years |
| Robert Yung | M | 61 |
University of California, Berkeley
| 6 years |
| Thomas E. Tighe | M | - |
University of California, Berkeley
| 7 years |
| Mark C. Holscher | M | - |
University of California, Berkeley
| 7 years |
| Jaideep Srivastava | M | - |
University of California, Berkeley
| 4 years |
| John Smither | M | 71 | 6 years | |
| Jin Long Chen | M | 61 | 4 years | |
| Rebecca M. Henderson | M | 63 | 11 years | |
| Cynthia Flowers | F | 64 | 5 years | |
| François de Carbonnel | M | 78 | 10 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 95 | 95.00% |
| United Kingdom | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Sean E. Harper
- Personal Network
